Nivolumab,Ipilimumab
BMS
['s1609', 'swog,1609']
megan othus will take the stage at #asco23 to share more about swog s1609. with colleagues michael j wagner et al, she previously shared powerful research on a substudy from the multicenter phase ii trial of swog s1609, cohort 51 in #jitc: 
The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Interim Editor-in-Chief: James L. Gulley (@gulley1)